CURIS INC 4

4 · CURIS INC · Filed Jun 8, 2007

Form 4

Period: 2007-06-06

VP, Research & Preclinical Dev

Transactions

Award
Non-qualified stock option (right to buy)
2007-06-06+70,233→ 70,233 total
Exercise: $1.39Exp: 2017-06-06→ Common stock (70,233 underlying)
Award
Qualified stock option (right to buy)
2007-06-06+71,942→ 71,942 total
Exercise: $1.39Exp: 2017-06-06→ Common stock (71,942 underlying)
Award
Qualified stock option (right to buy)
2007-06-06+79,767→ 79,767 total
Exercise: $1.39Exp: 2017-06-06→ Common stock (79,767 underlying)
Award
Non-qualified stock option (right to buy)
2007-06-06+78,058→ 78,058 total
Exercise: $1.39Exp: 2017-06-06→ Common stock (78,058 underlying)

Footnotes (2)

[F1]Options in the aggregate will vest 25% on the one-year anniversary grant date, or June 6, 2008. Remaining options will vest at 6.25% each successive three-month period, with non-qualified options vesting first. Options will be fully vested four years from the grant date.
[F2]Common stock subject to stock option award shall become exercisable on December 6, 2012 or upon the consummation of a collaboration, licensing or other similar agreement regarding the Targeted Cancer Drug Development Platform that includes an up-front cash payment of at least $10 million. For clarity, the cash payment shall be attributable to a nonrefundable license fee or other similar payment and shall not include an equity investment in Curis and any vesting is subject to such Executive Officer's continued service with the Curis.

Documents

1 file